Novel Blood Oxygenator Homogeneous Membranes

新型血液氧合器均质膜

• 批准号: 6933625
• 负责人: John J Bowser
• 金额: $ 13.17万
• 依托单位: COMPACT MEMBRANE SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6933625
• 关键词: artificial membranes; bioengineering /biomedical engineering; biomaterial compatibility; biomaterial development /preparation; biomaterial evaluation; biotechnology; blood oxygenator; extracorporeal circulation

DESCRIPTION (provided by applicant): Long-term blood oxygenators (BO) therapy requires non-porous membranes to limit BO wet out. Compact Membrane Systems (CMS) has identified (1) novel materials that can minimize wet out (while simultaneously maintaining needed gas-liquid transport of gases) and (2) a novel fabrication technique to make these materials into BO. In this Phase I program, CMS will combine these novel materials with novel fabrication technique to show the feasibility of an enhanced BO. We will analyze the system compared to existing BO controls for overall oxygen mass transfer and long-term stability. In-vitro testing will provide key performance and biocompatibility data. Parallel in-vivo studies (successfully completed in other programs) will provide key additional information on system capabilities. While CMS is confident that the novel fabrication technique can be applied to the novel materials, we have also identified parallel fabrication routes if the original process does not work.

描述（由申请人提供）： 长期血液充（BO）疗法需要非孔膜才能限制BO湿润。紧凑型膜系统（CMS）已经鉴定出（1）可以最大程度地减少湿润的新型材料（同时维持所需的气体液体运输气体）和（2）一种新型的制造技术，将这些材料制成BO。 在此I阶段计划中，CMS将将这些新型材料与新型制造技术相结合，以显示增强的BO的可行性。与现有的BO对照组相比，我们将分析该系统的整体氧气传质和长期稳定性。 体外测试将提供关键的性能和生物相容性数据。平行的体内研究（在其他程序中成功完成）将提供有关系统功能的关键其他信息。尽管CMS有信心可以将新型制造技术应用于新型材料，但如果原始过程不起作用，我们还确定了并行制造路线。